Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Pfizer (PFE) and Merck & Company (MRK)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amgen (AMGN – Research Report), Pfizer (PFE – Research Report) and Merck & Company (MRK – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Amgen (AMGN)
BMO Capital analyst Evan Seigerman maintained a Buy rating on Amgen today and set a price target of $372.00. The company’s shares closed last Tuesday at $338.59, close to its 52-week high of $346.85.
According to TipRanks.com, Seigerman is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Amgen with a $358.81 average price target, a 5.1% upside from current levels. In a report issued on January 22, DBS also maintained a Buy rating on the stock with a $400.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Pfizer (PFE)
In a report released today, Jason Gerberry from Bank of America Securities reiterated a Hold rating on Pfizer, with a price target of $27.00. The company’s shares closed last Tuesday at $25.77.
According to TipRanks.com, Gerberry is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pfizer with a $28.53 average price target, which is a 12.5% upside from current levels. In a report released yesterday, TipRanks – Anthropic also downgraded the stock to Hold with a $29.00 price target.
Merck & Company (MRK)
Goldman Sachs analyst Asad Haider maintained a Buy rating on Merck & Company today and set a price target of $133.00. The company’s shares closed last Tuesday at $115.84.
According to TipRanks.com, Haider is a 4-star analyst with an average return of
Merck & Company has an analyst consensus of Moderate Buy, with a price target consensus of $122.05, representing a 9.3% upside. In a report released yesterday, BMO Capital also upgraded the stock to Buy with a $135.00 price target.
